FDA allows Galectin Therapeutics to proceed with Phase 2 trial of belapectin + Keytruda in head and neck cancer

GALECTIN THERAPEUTICS INC

FDA issued 'Study May Proceed' letter for Phase 2 trial of belapectin + pembrolizumab as first-line therapy for recurrent/metastatic PD-L1 positive head and neck squamous cell carcinoma.
This IND is the company's second; prior investigator-initiated study provided rationale for combination.
Company expects to complete enrollment in pivotal NAVIGATE trial in NASH cirrhosis around end of 2022.
Company plans to engage potential partners for oncology program; financing and trial start could occur next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.